Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells In Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia

NCT02588456 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

5

Enrollment

OTHER

Sponsor class

Stopped This study was terminated due to lack of efficacy

Conditions

Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

Interventions

BIOLOGICAL: CART22 cells

Sponsor

University of Pennsylvania